1. Home
  2. NUV vs MLYS Comparison

NUV vs MLYS Comparison

Compare NUV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Value Fund Inc.

NUV

Nuveen Municipal Value Fund Inc.

N/A

Current Price

$8.08

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$13.66

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUV
MLYS
Founded
1987
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NUV
MLYS
Price
$8.08
$13.66
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $43.56
AVG Volume (30 Days)
1.3M
★ 1.8M
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 3.96%
N/A
EPS Growth
N/A
★ 37.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.02
$13.72
52 Week High
$9.26
$44.13

Technical Indicators

Market Signals
Indicator
NUV
MLYS
Relative Strength Index (RSI) 37.22 28.35
Support Level $8.05 N/A
Resistance Level $8.34 $30.72
Average True Range (ATR) 0.09 1.19
MACD -0.03 -0.02
Stochastic Oscillator 7.14 0.61

Price Performance

Historical Comparison
NUV
MLYS

About NUV Nuveen Municipal Value Fund Inc.

Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: